Affordable Access

Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease.

Authors
  • Jokinen, Mika J
  • Neuvonen, Pertti J
  • Lindgren, Leena
  • Höckerstedt, Krister
  • Sjövall, Jan
  • Breuer, Olof
  • Askemark, Yvonne
  • Ahonen, Jouni
  • Olkkola, Klaus T
Type
Published Article
Journal
Anesthesiology
Publication Date
Jan 01, 2007
Volume
106
Issue
1
Pages
43–55
Identifiers
PMID: 17197844
Source
Medline
License
Unknown

Abstract

Ropivacaine clearance is decreased in chronic end-stage liver disease. A normal dose can be considered for a single block in patients with liver impairment, because the peak plasma concentrations were essentially similar. When using a postoperative ropivacaine infusion in a patient with end-stage liver disease, the lowest effective dose should be used for the shortest possible time and the patient should be monitored closely, because systemic toxicity cannot be ruled out. Because of wide interindividual differences in pharmacokinetics in patients with liver disease, no definitive dosing instructions can be given.

Report this publication

Statistics

Seen <100 times